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TUMOR NECROSIS FACTOR ALPHA AND INTERLEUKIN-6 DRIVE A 
RANK-INDEPENDENT PATHWAY OF OSTEOCLAST ACTIVATION 
 
BRIAN M. FISSEL 
ABSTRACT 
 The skeleton is a dynamic organ that undergoes a continual process known as 
bone remodeling. Bone remodeling is necessary to maintain structural integrity, heal 
micro-fractures caused by from daily wear and tear, and to store and release essential ions 
and minerals. Remodeling is a highly regulated process, with bone resorption precisely 
balanced by bone formation under homeostatic conditions. In the setting of rheumatoid 
arthritis (RA), an inflammatory condition affecting joints, this balance is lost and bone 
around inflamed joints is eroded. These so-called “bone erosions” compromise joint 
function, causing disability. Osteoclasts, multinucleated cells of hematopoietic origin, are 
the only cells known to resorb bone. Osteoclasts are found at erosion sites in human 
joints, and data from mouse models of inflammatory arthritis suggest that osteoclasts are 
required for erosions to form in bone. The canonical pathway of osteoclast differentiation 
requires stimulation of myeloid precursors by the cytokine Receptor Activator of NF-κB 
ligand (RANKL) through its receptor, RANK. In the inflamed joint, RANKL expression 
can be induced on mesenchymal lineage cells by inflammatory cytokines such as tumor 
necrosis factor α (TNFα). Surprisingly, our lab observed bone erosions and osteoclast 
formation in a mouse model of RA in the absence of RANK.  Thus we hypothesized that 
in addition to RANKL expression, the cytokine milieu in RA may directly stimulate 
osteoclast formation. It was recently reported that the inflammatory cytokines TNFα and 
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interleukin-6 (IL-6) in combination stimulate osteoclast differentiation, independent of 
exogenous RANKL. We have reproduced these results and shown that these osteoclast-
like cells form entirely independently of RANK signaling. However, TNFα/IL-6 induced 
osteoclast formation still requires the transcription factor Nuclear Factor of Activated T 
cells (NFATc1), a master regulator of RANK-mediated osteoclast differentiation, as well 
as co-stimulatory signaling provided by the immunoreceptor tyrosine based activation 
motif (ITAM)-containing DNAX-activating protein (DAP12) molecules. We also showed 
that TNFα/IL-6 induced osteoclast formation requires activity of IL-6 receptor (IL-6R), 
as osteoclast formation can be inhibited through co-culture with an IL-6R blocking 
antibody (MR16-1). Finally, using an in vivo mouse model of RA in RANK-deficient 
mice, we tested whether blocking IL-6R with MR16-1 antibody protects against the 
formation of periarticular bone erosions. Our results suggest that a RANK-independent 
pathway of osteoclast formation contributes to inflammatory bone erosions. Targeting 
this pathway may improve outcomes for RA patients.  
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INTRODUCTION 
 
An Overview of Bone Biology 
 The skeleton is a dynamic and fascinating organ responsible for many functions. 
It acts as a series of levers for movement, protects vital organs, houses the bone marrow, 
and is the body’s primary repository for calcium and phosphate. Bone is a collagenous 
matrix impregnated with calcium phosphate crystals called hydroxyapatite, making it 
relatively light, but not brittle, and uniquely able to withstand both compressive and 
tensile forces.1 
 Macroscopically, bone is classified as either cortical or trabecular. Cortical bone 
is the hard, dense tissue that is found on the perimeter of bone. Trabecular bone is a 3-
dimensional latticework of arches and plates that come together to form a honeycomb-
like structure, which provides structural support to the bone and houses the marrow 
cavity.1 The skeleton is divided into two distinct anatomical groups: central (or axial) 
bones and peripheral (or appendicular) bones. Appendicular bones such as the long bones 
of the arms and legs comprise the majority of the bone mass in the skeleton and consist 
predominantly of cortical bone. Axial bones include the skull, spinal vertebrae, and 
pelvis, and contain substantial trabecular bone.2 
When viewed microscopically, adult bone is made up of many small layers of 
bone called lamellae, and hence is referred to as lamellar bone. Layers of dense bone 
called inner and outer circumferential lamellae run parallel to both the entire inner and 
outer layer of the bone.3 Running parallel to the long axis of the bone in between the 
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circumferential lamellae are osteons.  Osteons are circular structures that consist of a 
channel called a Haversian canal housing blood vessels, surrounded by multiple rings or 
lamellae of bone.3 
Bone is cellular and well vascularized. Three prominent resident cells of the bone 
are the bone-resorbing osteoclasts, bone-forming osteoblasts and the bone-monitoring 
osteocytes. Osteoclasts are large, multinucleated cells that are derived from myeloid 
precursors. Osteoclasts are the only cells in the body known to resorb bone, by which 
they can liberate calcium, phosphate, and the other organic and inorganic components of 
bone. Osteoclasts resorb bone by creating a sealed space called Howship’s Lacuna, into 
which they pump acid (H+) and proteases, such as cathepsin K, that hydrolyze and 
solubilize the bone, releasing its components.3 Osteoblasts are derived from 
mesenchymal stem cells and are responsible both for producing uncalcified bone material 
known as osteoid matrix and alkaline phosphatase, which facilitates incorporation of 
hydroxyapatite crystals into the osteoid matrix.3 Residing in small holes in between the 
lamellae are the other key resident cells of bone, osteocytes, differentiated osteoblasts 
which monitor bone quality and stress and orchestrate bone homeostasis by signaling 
osteoblasts and osteoclasts.1 Both osteoblasts and osteocytes are important sources of 
Receptor Activator of NF-κB ligand (RANKL), which is the primary cytokine 
responsible for stimulating osteoclast formation.4 
 Osteoblasts and osteoclasts interact with each other through paracrine factors and 
influence the formation and function of the other, linking bone formation and resorption 
in a process called osteoclast:osteoblast coupling.5 During growth and bone development, 
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bone formation exceeds resorption as the bones increase in length and size. However 
once the skeleton is fully formed, the skeleton is not static. In adults, bone is continually 
subject to the action of osteoclasts and osteoblasts, which actively resorb and replace 
existing bone, respectively, within the existing frame of the skeleton in a process called 
bone remodeling. 5 
 
Bone Remodeling 
 Bone remodeling serves two main purposes in the adult skeleton: (1) to maintain 
structural integrity by repairing microfractures caused by daily stresses and (2) to release 
calcium stored in the skeleton in order to fine-tune the concentration of this key ion in the 
extracellular space. Systemic hormones and paracrine cytokines regulate bone 
remodeling.6 However, only the role of cytokines in bone remodeling will be discussed 
herein, as the hormonal systems that regulate the skeleton are beyond the scope of this 
thesis.  
 Hormones and other biochemical signals recruit myeloid precursors to the bone 
surface. Osteoblasts and other stromal cells such as osteocytes and fibroblasts secrete 
macrophage colony-stimulating factor (MCSF) and RANKL, a member of the tumor 
necrosis factor (TNF) family.7 MCSF binds to the receptor c-Fms and RANKL binds to 
the receptor RANK on myeloid precursors, causing them to fuse together, differentiate 
into large multinucleated osteoclasts, and begin to excavate a cavity into the bone.7 
Osteoblasts also produce a soluble ligand known as osteoprotegerin (OPG), which can 
bind RANKL, preventing it from activating RANK and limiting the number of 
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osteoclasts formed.5 After osteoclasts are formed and begin resorbing bone, osteoblast 
progenitors are recruited through undefined mechanisms from the marrow stroma to the 
site of resorption where they differentiate and secrete osteoid matrix that will ultimately 
be mineralized to form calcified bone.5 
 Individuals reach peak bone mass in early adulthood, and in healthy adults the 
rate of bone resorption closely matches the rate of formation, so that bone mass remains 
relatively constant throughout adulthood.6 If this precise balance is lost, bone disease 
results. 
 
Bone Diseases from an Imbalance in Bone Remodeling 
 When balanced bone remodeling is disturbed by reduced resorption, it leads to a 
condition called osteopetrosis. In these individuals, osteoblast bone formation may be 
normal or even reduced, but the ability to resorb bone by osteoclasts is absent.8 
Commonly this is due to mutations in various genes involved in maintaining an acidic 
environment at the bone surface, rendering osteoclasts unable to resorb bone 
efficiently.9,10 Osteopetrosis can be quite debilitating, and the excessive bone mass can 
lead to paralysis, blindness, or deafness due to narrowing of bone around nerves and the 
spinal cord.8 It can also lead to hypocalcemia due to inability of osteoclasts to liberate 
calcium from bone.8 Fortunately, because osteoclast precursors are derived from bone 
marrow hematopoietic stem cells, osteopetrosis can be sometimes be cured with an 
allogeneic HLA-identical bone marrow transplant, which replaces the non-functional 
osteoclasts with normal ones.9 
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 At the other end of the spectrum are diseases where resorption exceeds formation, 
such as the most common bone disease: osteoporosis. In osteoporosis, decreased bone 
mass greatly increases the risk of vertebral and hip fractures.11 Decreases in bone mass 
are challenging to manage because they can be due to either a loss of normal osteoblast 
activity, excessive osteoclast resorption, or a combination of the two. 6 
 Another disease characterized by excessive bone loss is inflammatory arthritis, 
where the bone loss is focal and localized around joints, resulting in periarticular 
erosions. In the case of inflammatory arthritis, such as rheumatoid arthritis, bone loss 
occurs as a result of pathologic osteoclast activity.12 
 
An Overview of Rheumatoid Arthritis 
 Rheumatoid arthritis falls under a broader category of diseases known generally 
as “arthritis”. The meaning of the word arthritis can be traced back to its root words, 
“arthron” and “itis", the Greek words for joint and inflammation, respectively, giving us 
its meaning, “joint inflammation”.  There are over 100 different diseases (e.g., gout, 
rheumatoid arthritis, ankylosing spondylitis, lupus) that are clinically encompassed under 
the term arthritis. Each disease affects different joints and other sites of the body with 
variable age of onset, etiology and severity. 13 
 Although arthritic diseases may not have the reputation of diseases like heart 
disease or cancer, the burden of arthritis is considerable, both to the individual and our 
economy. Arthritic diseases are the leading cause of disability in the United States; by 
2012 an estimated 52.5 million adults had been diagnosed with arthritis, 22.7 million of 
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which had activity limitation due to the disease.14 Arthritis is not limited to the elderly, as 
people under the age of 65 account for two-thirds of individuals with arthritis, including 
300,000 children.15 Forty-four million outpatient visits and 992,100 hospitalizations are 
attributable to arthritis annually, with economic costs tallied at $128 billion in 2003 
alone. 14 
 Of the many types of arthritis, three of the most common forms are osteoarthritis, 
rheumatoid arthritis (RA), and juvenile arthritis. The focus of this thesis is RA, which is a 
specific form of “inflammatory” arthritis. About 1.5 million people in the US and 1% of 
the adult population worldwide are affected by RA. This disease afflicts women at a rate 
of two to three times more than men.16 RA may occur at any age but the risk of 
developing this disease increases as people get older. Most typically, it occurs in women, 
between the ages of 30 and 60, as opposed to between 60 and 80 in men. 12 
RA is a systemic disease that is the result of an autoimmune reaction, where the 
immune system mistakenly identifies self-tissues as foreign and mounts an immune 
response against them. In the case of RA, the immune system targets primarily the 
synovial tissue, the thin membrane that surrounds joints, leading to chronic inflammation 
and destruction of the joints, although it can also affect other organs.16 The disease 
generally follows one of three courses: 1) most frequently the disease is chronic with no 
periods of remission and progressively worsens; 2) some patients experience only one 
episode of disease activity that can last from two to five years and then never reoccurs; or 
3) patients can also be relatively disease free, but experience periodic episodes of acute 
inflammation. 17 
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Figure 1. The normal joint and the changes caused by RA. (A) The components of a normal 
synovial joint. (B) The features and cells involved in a rheumatic joint, including synovial 
hyperplasia, pannus formation, and focal bone erosions. (C) X-ray of normal metacarpophalangeal 
joints. (D) X-ray of metacarpophalangeal joints from a patient with RA. Bone erosions are 
highlighted by red arrows, and joint narrowing due to cartilage degradation by gold arrows. 
(Figure adapted from Smolen, Steiner, 2003).18 
 
Rheumatoid arthritis is defined as chronic inflammatory arthritis affecting at least 
five joints; if less than five joints are affected the disease is characterized as 
undifferentiated inflammatory arthritis.19 The presenting symptoms are tender and 
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swollen joints in a symmetrical distribution; fatigue and occasional fevers; and early 
morning pain and stiffness lasting for more than an hour that improves with physical 
activity. 20 The most commonly affected joints are the wrists, the metacarpophalangeal, 
and proximal interphalangeal joints, while involvement of larger joints, such as the knees 
and shoulders are less common, and usually occurs in later disease stages. Unhindered 
disease activity leads to destruction of bone, cartilage, and malignant transformation of 
the synovium and results in pain and deformity at the joint, and deterioration of joint 
function (Figure 1).19 Extra-articular manifestations of RA are less common but can also 
lead to morbidity and include subcutaneous nodules, interstitial lung disease, 
cardiomyopathy, rheumatoid vasculitis, anemia, and lymphoma. 19 About 70% of patients 
with RA test positive for rheumatoid factor (RF), an auto-antibody targeted against the 
constant (Fc) region of IgG.12 While RF may be present in people who do not meet the 
criteria of RA, its presence is indicative of higher risk of developing RA, and higher 
levels of rheumatoid factor correlate with increased disease severity.12  
There is currently no cure for RA. Therefore the goal of treatment is to alleviate 
symptoms by reducing pain and inflammation and thus allow patients to return to a 
relatively normal level of activity.16 Reducing inflammation also diminishes joint 
damage, which prevents chronic disability in the long-term.19 While adopting healthier 
lifestyle habits and surgery are options for treatment, they can only do so much, and in 
the case of surgery is generally only for very advanced stages of the disease.19 For these 
reasons, medication is the predominant treatment for RA. The pathology of RA is 
mediated by the inflammatory response. Therefore the strategy with drug treatment is to 
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block inflammatory cytokines such as tumor necrosis factor (TNF) alpha and interleukin-
1 (IL-1) to try to reduce inflammation. Another common strategy that anti-rheumatic 
drugs take is to reduce activation of B- and T-cells that are commonly overactive in RA.20 
Unfortunately these drugs also reduce the ability of the immune system to fend off 
infections and cancer. Therefore, efforts continue to increase our understanding of the 
pathophysiology of RA.  
 
Bone Pathology of Rheumatoid Arthritis 
 The research in the Aliprantis laboratory is focused on bone physiology, 
consequently the scope of the discussion of RA pathology will be limited to the effects 
seen on periarticular bone, specifically erosions, with a limited discussion of synovial 
inflammation and hyperplasia, and articular cartilage degradation. 
 Bone erosions in RA occur soon after onset of the disease, within 3 months for up 
to a quarter of RA patients, and within 2 years for 75% of patients.21 In RA the most 
common type of bone loss seen is erosions on periarticular bone at the pannus-bone 
interface, commonly referred to as focal bone erosions (Figure 1D).19 Periarticular bone 
is the layer of bone found directly underneath and adjacent to the articular cartilage, the 
protective lining covering the epiphyses (the ends of the long bones) at the joints. 
Chronic inflammation in RA causes hyper-proliferation of synovial tissue, resulting in the 
development of a structure called the pannus.19 The pannus is an abnormal cellular layer 
of malignant synovial/fibrovascular tissue which in RA secretes pro-osteoclastogenic 
molecules including RANKL and inflammatory cytokines.22,23 Osteoclasts are implicated 
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in causing these erosions and have been found in resorption pits at the pannus-bone 
interface, as well as in erosions near where the synovial membrane inserts in the 
periosteal surface at the edge of the articular cartilage. 22  
 While it is well-known that the initiating events in RA are loss of self-tolerance in 
the immune system, resulting in inflammation and synovial hyperplasia, focal bone 
erosions, and degradation of the articular cartilage, the initiating events that trigger RA 
are unclear.19 Some environmental factors such as tobacco smoke, silicone dust, and 
mineral oil have been linked to increased auto-antibodies in the blood, which could be the 
result of triggering innate immune cells through toll-like receptors in a dysregulated 
fashion, leading to proinflammatory cytokines and the activation of adaptive immunity.19 
Another theory is that self-reactive T-cells are allowed to leave the thymus, which then 
initiate an inflammatory response, activate auto-antibody-producing B cells, and recruit 
innate immune cells that release pro-inflammatory cytokines.24 
 Many different types of immune cells are found in the inflamed joint, including T 
cells, B cells, plasma cells, dendritic cells, mast cells, and granulocytes, and many of 
these play important roles in driving the pathogenesis of RA, generally, and focal bone 
erosions, specifically (Figure 1B).19 T cells make up the largest population of immune 
cells in the inflamed joint, and are believed to play a critical role in driving inflammation 
and bone erosions.25,26 
 While CD8+ T cells are present in the joint and contribute to some of the 
pathology in RA, the CD4+ T helper cell population plays a critical role in driving the 
disease through both direct and indirect mechanisms. CD4+ T helper (TH) cells are 
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capable of differentiating into more defined lineages, and their fate is determined by 
which cytokines they encounter.27 There are 4 lineages of TH cells are that are known to 
affect osteoclast differentiation: the regulatory T cells (Treg), TH1, TH2, and TH17 
subsets.19 TH1 cells primarily produce the cytokines interferon-γ, interleukin-2 (IL-2), and 
tumor necrosis factor α (TNFα) and activate macrophages, CD8+ T cells, and 
immunoglobulin G (IgG)-producing plasma cells.27 TH2 cells secrete IL-4, IL-5, IL-10, 
and IL-13 and activate B cells.27 Treg cells produce IL-4 and IL-10. Overall, Treg, TH1, and 
TH2 cells are thought to inhibit bone resorption by osteoclasts. 
 In contrast, the population of TH17 cells are critical drivers of osteoclastogenesis 
and bone resorption in inflamed joints.28 Upon exposure to IL-1, IL-6, or IL-23 
(cytokines found in inflamed RA joints), naïve T helper cells differentiate into TH17 cells, 
and secrete numerous cytokines, the most relevant of which are IL-6, IL-17, and 
TNFα.19,28 TH17 cells are potent osteoclast activators, and even express membrane-bound 
RANKL, although that is not thought to be the primary method by which they driving 
osteoclastogenesis.24,29 It is thought the most potent way that they drive osteoclast 
differentiation is through their secretion of IL-17 and TNFα, which induces RANKL 
expression in osteoblasts and other stromal cells.30 
 Other cell populations that contribute to chronic inflammation are activated B 
cells (known as plasma cells), synovial macrophages, and synovial fibroblasts. Plasma 
cells produce antibodies, and in the case of RA, auto-antibodies like rheumatoid factor 
that can aggregate and promote the release of pro-inflammatory chemokines.31 Synovial 
macrophages are considered to be the predominant source of pro-inflammatory cytokines 
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in inflamed joints in RA. They release many cytokines that promote osteoclast formation 
including TNF-α, IL-1, and IL-6.32 Synovial fibroblasts produce the same cytokines, and 
in addition also express RANKL in patients with RA.33  
TNF-α, IL-1, and IL-6 are especially potent drivers of osteoclast differentiation 
because they affect osteoclast formation both directly and indirectly. Similar to IL-17, 
these cytokines induce expression of RANKL on osteoblasts and on synovial 
fibroblasts.19,34 These cytokines also act directly on osteoclasts to promote 
osteoclastogenesis, in combination with RANKL in the case of IL-1 and TNFα.35,36 
Recent and somewhat controversial findings suggest that TNFα and IL-6 are also capable 
of promoting osteoclastogenesis independent of RANKL.37 
As was mentioned earlier, under physiologic conditions, bone resorption by 
osteoclasts is closely matched by new bone formation by osteoblasts in a process called 
coupling. Therefore when bone resorption increases, a similar increase in bone formation 
is usually seen. One way this is achieved in healthy bone is that osteoclasts secrete a 
number of factors to promote bone formation by stimulating osteoblast differentiation, 
including tartrate-resistant acid phosphatase (TRAP; a common protein also used to 
identify osteoclasts), sphingosine-1-phosphate, and semaphorin 4D, among others.38A 
key pathophysiological event in the arthritic joint that causes bone erosions to form, 
however, is the loss of coupling between osteoclasts and osteoblasts.38 
The presence of pro-inflammatory cytokines contributes to this uncoupling, 
through both direct and indirect mechanisms. In addition to their pro-osteoclast effects, 
TNFα and IL-1 have also been shown to inhibit osteoblast maturation and function by 
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down-regulating alkaline phosphatase and type 1 collagen expression.39 TNFα also drives 
uncoupling by increasing the expression and secretion of soluble inhibitors of the 
Wingless (Wnt) pathway, such as the Dickkopf-1 (DKK1), in synovial fibroblasts.39 Wnt 
signaling is necessary for differentiation of osteoblasts, and by inhibiting Wnt signaling, 
DKK1 is able to prevent osteoblast differentiation and limit new bone formation at the 
inflamed joint.4 
 
Cellular Origins and Molecular Biology of the Osteoclast 
 As important mediators of skeletal health and disease, it is important to 
understand the cellular progenitors that give rise to osteoclasts as well as the external and 
internal molecules important for osteoclast differentiation.  
 Unlike osteoblasts, osteoclasts are cells derived from HSCs (hematopoietic stem 
cells). Precursor cell populations are commonly defined by unique surface markers and as 
cells become more defined, they lose the capacity to differentiate into other cell types. To 
become osteoclasts, MCSF stimulates HSCs to differentiate into CMPs (common 
myeloid progenitors) which upon further MCSF stimulation develop into MDPs 
(macrophage/dendritic cell progenitors), which differentiate into monocyte/macrophage 
or CDP lineages (common dendritic cell precursor).40 Cells from the 
monocyte/macrophage lineage then further differentiate into myeloid blast cells and/or 
monocytes, which then are capable of differentiating into osteoclasts upon MCSF and 
RANKL stimulation.40 It is important to note that cells in the dendritic and macrophage 
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lineages retain some osteoclast differentiation potential, although this is dependent on 
micro-environmental stimuli, and their expression of RANK.40 
 The population defined as bone marrow osteoclast precursors in mice express low 
levels of the surface protein CD11b and high amounts of the marker Ly6C (CD11b-
/loLy6Chi or OCP). Additionally they are negative for CD3, B220, and Ter119, markers 
for T cells, B cells and erythroid cells, respectively.41 Additionally, there also are more 
terminally differentiated OCPs circulating in the peripheral blood called circulating 
quiescent lineage committed OCP (QOP). QOP populations have been shown to increase 
during inflammatory states and are associated with bone loss.42 
 What happens when MCSF and RANKL act on osteoclast precursors? MCSF is 
essential to “prime” precursor cells of the monocyte lineage by binding to its receptor c-
Fms, thus activating proliferation and inducing expression of RANK.43 RANK and 
RANKL are members of the TNF family of receptors and cytokines, respectively. 
RANKL acts through RANK, which associates with TNF-receptor-associated factors 
(TRAFs) to activate canonical and non-canonical NF-κB pathways and the mitogen-
activated kinase (MAPK) pathway leading to activation of cAMP-response element-
binding protein (CREB) (Figure 2).44 
Osteoclast differentiation also requires a signal cascaded initiated by co- 
stimulation with two membrane-bound adapter molecules, DAP12 and Fc receptor 
common γ subunit (FcRγ).45 These adapter molecules contain an immunoreceptor 
tyrosine-based activation motif (ITAM) and associate with innate immune receptors such   
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Figure 2. Signal cascades activated by RANK and innate immune receptor co-stimulation in 
osteoclast precursors. Ligation of the RANK receptor with RANKL initiates activation of many 
signaling pathways including NF-κB, MAPK, leading to the activation of transcription factors 
necessary for osteoclast formation. RANK also works in synergy with ITAM-mediated co-
receptor stimulation to activate intracellular calcium signaling, enabling the activity of NFATc1, 
the master transcription factor of osteoclast differentiation. (Figure taken from Okamoto, 
Takayanaki, 2011).43  
 
as triggering receptor expressed on myeloid cells 2 (TREM2) and osteoclast associated 
receptor (OSCAR).45 Tyrosine phosphorylation of the ITAM enables phosphorylation of 
phospholipase-Cγ2 to increase intracellular calcium (Figure 2).46 
This calcium signal activates 2 calcium/calmodulin-dependent pathways: protein 
kinase type IV (CaMKIV) and the phosphatase, calcineurin. CaMKIV acts in concert 
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with CREB and NF-κB to induce c-Fos which, along with Jun, comprises the 
transcription factor AP-1. CREB and AP-1 induce nuclear factor of activated T cells 
cytoplasmic 1 (NFATc1), the master regulator of osteoclast differentiation (Figure 2).44 
In order for NFATc1 to translocate to the nucleus, it requires dephosphorylation by the 
phosphatase calcineurin, which is also activated by the increase in intracellular calcium. 
NFATc1 binds to its own promoter providing auto-amplification, enhancing its ability to 
activate genes essential for osteoclast multinucleation, differentiation and function 
(Figure 2).47 Additionally NFATc1 also induces expression of Blimp1, a transcriptional 
repressor of negative regulators of osteoclast genes, removing inhibitory mechanisms of 
osteoclastogenesis.44  
The importance of these molecular drivers of osteoclastogenesis is highlighted by 
observing the defects that occur upon deletion of these genes in mice. RANK signaling is 
critical at several stages of this signaling cascade, and osteoclast precursors that are 
deficient for RANK are unable to form osteoclasts upon RANKL stimulation. RANK 
signaling is critical for normal development of the bone, and mice with a germ-line 
deficiency in the gene encoding RANK have skeletons composed of unresorbed 
embryonic calcified cartilage without well-formed cortices, the target of inflammatory 
bone erosion, and are thus protected from bone erosions in some mouse models of 
inflammatory arthritis.48 DAP12 is essential for normal osteoclast formation, and mice 
with germ-line deletion of Dap12 develop osteopetrosis, a phenotype that is exacerbated 
by simultaneous deletion of FcRγ.49 Mice with homozygous deletion of Nfatc1 are not 
viable and die during embryonic development. However the bone-specific requirement of 
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NFATc1 is revealed by post-natal deletion of Nfatc1 in mice, which causes the 
development of severe osteopetrosis.47,50 
 
Role of RANK in Development of Periarticular Bone Erosions 
 The presence of osteoclasts at erosions sites in both humans and murine models of 
inflammatory arthritis strongly suggests that they are responsible for these lesions.22,51 
Given the critical role that RANK plays in driving osteoclastogenesis, diseases featuring 
excessive bone resorption can be treated with a monoclonal RANKL blocking antibody 
like Denosumab, which prevents RANKL from activating osteoclasts through RANK.52 
Our lab hypothesized that if osteoclasts are essential to the formation of periarticular 
bone erosions, and if RANK-RANKL signaling is essential to osteoclast differentiation, 
then deletion of RANK in osteoclast precursors should protect against the formation of 
erosions in arthritic mice.  
 In experiments carried out by Drs. Julia Charles and William O’Brien, our 
laboratory tested this hypothesis using a common murine model of rheumatoid arthritis, 
K/BxN serum transfer arthritis.  In the K/BxN model, joint inflammation is transiently 
induced by administering serum from transgenic mice that spontaneously develop 
arthritis (K/BxN mice).53 This serum contains autoantibodies that target joint tissues to 
promote inflammation. Arthritis was induced in mice where RANK had been 
conditionally deleted in osteoclast precursors at 8 weeks of age, after normal skeletal   
development had occurred. The presence of bone erosions was determined by analyzing 
the paws with micro-computed tomography (micro-CT). Joint histology was also 
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performed, with tissues stained with hematoxylin and eosin (H&E) and TRAP, a marker 
of osteoclasts. Surprisingly, mice deficient for RANK showed only partial reduction in 
both periarticular bone erosions by micro-CT (Figure 3), and TRAP-positive osteoclast 
cells by histology (data not shown). This observation suggests that RANK-independent 
pathways may contribute to osteoclast formation and bone erosion in inflammatory 
arthritis.  
  In support of the existence of RANK-independent pathways of osteoclast 
differentiation, it was recently reported by Yokota, et al. that the combination of TNFα 
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and IL-6 induces the formation of TRAP-positive osteoclast-like cells that were capable 
of resorption both in vitro and in vivo, independent of RANKL.37 Based on this report, 
our findings in Figure 3, we set out to explore how TNFα and IL-6 promote 
osteoclastogenesis and whether the combination of these cytokines result in bone 
resorption in inflamed joints. 
 
Specific Aims and Objectives 
 Periarticular bone erosion is a hallmark manifestation of RA and other 
inflammatory arthritides, and leads to joint destruction causing significant disability in 
RA. While controlling synovitis reduces inflammation and consequent bone erosion, even 
patients in remission or low disease activity may actively develop erosions.54,55 
Osteoclasts, the only known cell type capable of resorbing bone, are found at erosion 
sites in human joints and data from mouse models of inflammatory arthritis suggest that 
these cells are required for erosion formation.22,51,56 Osteoclasts are multinucleated cells 
that differentiate from myeloid precursors under the influence of the cytokine RANKL. 
Under normal physiological conditions, RANKL is made by osteocytes and stromal cells 
in the bone.57,58 In the inflamed joint, RANKL is also produced by activated T-cells and 
synoviocytes and is induced in stromal cells by inflammatory cytokines such as TNFα.24 
As discussed in more detail above, RANKL binds to its receptor on osteoclast precursors, 
RANK, and activates a signaling cascade that results in the expression and activation of 
the key osteoclast transcription factor, NFATc1.59 NFATc1 drives transcription of genes 
important for osteoclast multinucleation and bone resorption. It is clear that the cytokine 
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milieu in RA promotes osteoclast differentiation through induction of RANKL, but it is 
not known whether the inflammatory environment has RANK-independent effects on 
osteoclast formation. It has recently been shown that osteoclastogenesis can be driven by 
the combination of TNFα and IL-6, both cytokines that are elevated in RA.37 This 
suggests the possibility that alternative pathways of osteoclast formation are playing a 
role in RA bone erosions.  
Our research seeks to understand whether TNFα/IL-6 driven osteoclastogenesis is 
independent of RANK, using osteoclasts genetically deficient for RANK. We also aim to 
understand how these alternatively formed osteoclasts are similar to or different than 
classic RANKL driven osteoclasts in their precursor identity, resorptive function, 
expression of mature osteoclast markers, and transcriptional and signaling requirements 
for formation. Finally, we test the hypothesis that blocking IL-6 signaling reduces 
TNFα/IL-6-induced osteoclastogenesis in vitro. Moreover, we seek to determine whether 
blocking IL-6 receptor signaling in RANK-deficient mice reduces periarticular erosions 
in serum transfer arthritis. 
Aim 1: Verify that TNFα/IL-6 induced osteoclastogenesis is independent of 
RANK signaling using osteoclast precursors deficient for RANK.  
Aim 2: Determine which myeloid progenitor populations are capable of 
differentiation into osteoclasts in response to TNFα/IL-6 and if it is the same population 
as for RANKL-induced osteoclasts. 
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Aim 3: Determine if the osteoclast transcriptional and differentiation program 
induced by TNFα/IL-6 is similar to or different from classical RANKL-driven 
osteoclasts.  
Aim 4: Determine if TNFα/IL-6-induced osteoclasts are capable of resorbing 
bone.  
Aim 5: Determine if TNFα/IL-6 induced osteoclastogenesis is dependent on 
NFATc1, the key transcriptional regulator of RANKL induced osteoclastogenesis.  
Aim 6: Determine if TNFα/IL-6 induced osteoclastogenesis requires the same 
innate immune receptor co-stimulation necessary for classical RANKL-driven 
osteoclastogenesis.  
 Aim 7: Show that IL-6 signaling through the IL-6 receptor is essential to 
formation of TNFα/IL-6-induced osteoclasts in vitro. 
 Aim 8: Determine if blockade of IL-6 signaling in vivo with an anti-mouse IL-6R 
antibody prevents bone erosions in RANK-deficient mice given serum transfer arthritis. 
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METHODS 
 
Mice 
 Rankfl/fl mice were a gift of Dr. Josef Penninger; NFATc1fl/fl mice were generated 
in the lab as described in Aliprantis et al.47 RANKfl/fl and NFATc1fl/fl mice were mated to 
Mx1-Cre+ mice (Jackson Laboratories, Bar Harbor ME) to generate RANKfl/fl and 
NFATc1fl/fl Mx1-Cre+ mice. Sex matched littermate mice lacking Cre recombinase were 
used as controls. Mice homozygous for the floxed Rank and Nfatc1 alleles and 
hemizygous for Mx1-Cre are viable, fertile, and display no hematopoietic abnormalities. 
Bones from Dap12-/- and Dap12-/-, Fcrγ-/- mice were a gift of Dr. Mary Nakamura, 
University of California, San Francisco. All strains were on a C57BL/6 background. All 
mice were maintained under specific pathogen-free conditions, and all animal research 
was conducted with the approval of the Institutional Animal Care and Use Committee of 
Harvard Medical School and conformed to relevant guidelines and laws.  
 
Deletion of RANK and NFATc1 in C57BL/6 Mice 
Rankfl/fl;Mx1-Cre+ and Nfatc1fl/fl;Mx1-Cre+ mice were treated at 8 weeks of age 
with polyinosinic-polycytodylic acid (poly I:C; Sigma-Aldrich) to induce deletion of the 
floxed alleles in early hematopoietic progenitor cells.  
Poly I:C is a synthetic double-stranded RNA that induces interferon alpha and 
beta expression, which leads to expression of the Mx1-Cre transgene, and subsequent 
deletion of any floxed genes. Mice receive three doses of 250 μg of poly I:C given every 
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two days. Two weeks after treatment with poly I:C, floxed alleles of Rank and Nfatc1 
have a deletion efficiency of greater than 95% in hematopoietic tissues. Mice with MxCre 
driven deletion of Rank and Nfatc1 are henceforth referred to as RankΔ/Δ and Nfatc1Δ/Δ 
mice, respectively. 
Similarly treated sex-matched littermate Rankfl/fl;Mx1-Cre- mice and Nfatc1 
fl/fl;Mx1-Cre- mice were used as controls and are henceforth referred to as RankWT and 
Nfatc1WT, respectively. 
 
IL-6 Receptor Blockade of RANKΔ/Δ Mice with Serum-Transfer Arthritis 
 K/BxN mice are transgenic mice expressing the KRN T-cell receptor and the 
MHC class II molecule Ag7, and spontaneously develop severe inflammatory arthritis. 
Serum from these mice contains pathogenic autoantibodies that when administered to 
other mouse strains induces a similar arthritis phenotype, which is transient and will 
subside with time. This model is commonly used to study rheumatoid arthritis in mice. A 
schematic of the experiment is detailed in Figure 4. 
 Age-matched male RankWT and RankΔ/Δ mice were injected with 200 μL of pooled 
K/BxN arthritogenic serum by intraperitoneal injection on days 0 and 2 via 
intraperitoneal injection. Mice of each genotype were randomly assigned to 
simultaneously receive either a blocking monoclonal antibody against IL-6 receptor 
(MR16-1; Genentech) or Fc IgG2a isotype control (BioXCell) via intraperitoneal 
injection. Mice were given a loading dose of 400 μg of antibody on day 0, and doses of 
200 μg of antibody each on days 3, 6, 9, and 12. Disease severity was assessed every 2 
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days by clinical scoring and measurement of change in ankle thickness. Mice were scored 
for clinical severity using a qualitative swelling score of 0-3 per paw for a maximum total 
score of 12. Wrist and ankle thickness were measured with calipers, and disease severity 
was measured by comparing change in thickness from day 0. Clinical assessment was 
performed by an investigator blinded to genotype and antibody treatment. Mice were  
sacrificed on day 14 by carbon dioxide asphyxiation followed by cervical dislocation.  
 
Serum, fore paws, hind paws, and bone marrow from the femur/tibia were collected from 
each mouse for analysis.  
 
In vitro Assays for Osteoclast Differentiation 
 Bone marrow cells (BMCs) were harvested from the femurs and tibias of 12-16 
week old mice using sterile technique. BMCs were cultured in osteoclast media (OC 
media), composed of α-minimum essential medium with ribonucleosides (Cellgro) 
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supplemented with 10% HyClone fetal bovine serum (Thermo Scientific) and 50 units/ml 
penicillin/streptomycin (Sigma-Aldrich). Cells were plated in triplicate at a density of 3 x 
104 cells/well in the presence of 10 ng/ml macrophage colony-stimulating factor (MCSF; 
R&D Systems) in 96-well flat-bottom plates and osteoclast precursors were expanded for 
2 days.  
 Following the 2-day expansion of osteoclast precursors in MCSF, the wells were 
washed to remove non-adherent cells and the remaining bone marrow-derived 
macrophages (BMMs) were further cultured in OC media supplemented with 10 ng/ml 
MCSF and either 5 ng/ml murine RANKL (PeproTech), 50ng/ml murine TNFα 
(PeproTech), 50ng/ml murine IL-6 (R&D Systems) or combined TNFα and IL-6. After 3 
days, fresh cytokines (MCSF, RANKL, TNFα, and IL-6) were replenished by adding 
10% of the volume of the media in the well 10X concentrated cytokines diluted in OC 
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media. In some experiments, osteoprotegerin (OPG; R&D Systems) was added 
simultaneously with RANKL or pro-inflammatory cytokines. For IL-6R blocking 
experiments, anti-mouse IL-6 Receptor antibody (MR16-1; Genentech) or control anti-
mouse Fc-IgG2a antibody (BioXCell) were added 30 minutes before the addition of 
RANKL or pro-inflammatory cytokines. After 5 days the cells were fixed in 3.7% 
formaldehyde, and stained for tartrate-resistant acid phosphatase (TRAP) using the Acid 
Phosphatase Kit (Sigma-Aldrich) according to the manufacturer’s instructions. A 
schematic diagram of the assays is depicted in Figure 5. Osteoclasts were quantified by 
counting TRAP-positive multinucleated cells with 3 or more nuclei per cell. All images 
were taken using a Nikon TMS-F inverted microscope at a total magnification of 100X.  
 
In vitro Assays for Osteoclast Resorption 
 In order to measure resorptive function in TNFα/IL-6-induced osteoclasts, 
osteoclasts were grown on either dentin, commercially available human bone particles 
(OsteoAssay Wells, Lonza), or hydroxyapatite coated wells (OsteoLogic slides, BD), 
which were then assayed for differences in resorption of dentin and cleavage of bone 
matrix as described below. A schematic diagram of the culture methodology for 
resorption assays is depicted in Figure 5. 
Dentin slices were sterilized with 70% ethanol and incubated overnight in fetal 
bovine serum in a 96-well plate. BMCs were prepared and cultured as described above, 
but to allow time for resorption, cultures were continued for 14 days in the presence of 10 
ng/ml MCSF and 5 ng/ml RANKL or TNFα and/or IL-6, which were replenished every 
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2-3 days. After 14 days, cells were removed with bleach and cell-free dentin was stained 
for 2 hours with 1 mg/ml wheat germ agglutinin (WGA)-lectin-Alexa fluor 555 (Life 
Technologies), which binds to exposed collagen 1 fragments found in resorption pits. 
Bone slices were washed to remove unbound lectin, and resorption pits were visualized at 
a total magnification of 100X using a Nikon TE2000-U inverted Microscope with a C1 
Plus confocal system and a red laser (453 nm) at the Confocal Microscopy Core Facility 
at Brigham and Women’ Hospital (Boston, MA).  
OsteoAssay Wells, which contain a thin layer of adherent human bone particles 
were washed with PBS and then incubated for one hour to overnight in FBS. BMCs were 
cultured as for dentin slices and resorption activity was measured after 12 days by 
enzyme-lined immunoassay (ELISA) to detect carboxy-terminal collagen crosslinks 
(CTX) in culture supernatants. 
OsteoLogic plates, which are coated with a thin layer of hydroxyapatite to mimic 
the mineral component of bone, were washed with PBS and then incubated for one hour 
to overnight in FBS. BMCs were cultured as for dentin slices. After 14 days, the cells 
were removed with 10% bleach and the wells were washed with deionized water to 
remove free calcium. A Von Kossa stain was then used to visualize cleavage of calcium 
phosphate. The wells were stained with 5% (w/v) silver nitrate, which reacts with 
phosphate in a precipitation reaction, and the wells are then developed with 1% 
pyrogallol to visualize areas of resorption. All images were taken using a Nikon TMS-F 
inverted microscope at a total magnification of 100X. 
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Real-time Quantitative PCR Analysis 
 Real-time quantitative polymerase chain reaction (qPCR) is a sensitive way to 
quantitatively compare RNA abundance between samples. We used qPCR to identify 
differences or similarities in the transcriptional profile of RANKL and TNFα/IL-6-
induced osteoclasts. In qPCR the RNA that is to be tested is converted into 
complimentary DNA (cDNA) by the enzyme reverse transcriptase. The resultant cDNA 
abundance is proportional to the abundance of a given RNA transcript. Amplification of 
the cDNA template corresponding to the RNA of interest is performed by PCR using 
primers that are specific to the gene to be detected. We performed amplification using the 
Fast SYBR Green Master Mix (Life Technologies), which contains SYBR Green I dye, 
which binds to all double-stranded DNA. As the amount of PCR product increases, the 
fluorescence intensity increases proportionally. 
Osteoclasts to be used for gene expression analysis were cultured as described for 
osteoclast differentiation assays above, except that they were plated at a density of 9 x 
104 cells in 48-well plates. For each condition, 6 replicate wells were lysed by Trizol 
reagent (Life Technologies) and pooled. Samples were collected 4 days after addition of 
RANKL and TNFα and/or IL-6. RNA was isolated according to the Trizol reagent 
protocol. Total RNA (2 μg) from each sample was used to create cDNA with hexamer 
random priming and reverse transcriptase from the affinity script qPCR cDNA synthesis 
kit (Agilent Technologies). One sample was run with no reverse transcriptase and used as 
a negative control. RT-PCR reactions were run on an Mx3005P qPCR system (Agilent  
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Technologies) using 50 ng of cDNA per well with each sample run in duplicate. Two 
negative controls were run for each primer pair, and all mRNA levels for each target gene  
were normalized to the house keeping genes hypozanthine phosphoribosyltransferase 
(Hprt) or glyceraldehyde 3-phosphate dehydrogenase (Gapdh). Primer sequences are 
listed in Table 1. Quantification was done using CT values, which are the fractional cycle 
numbers at which fluorescence passes a fixed threshold. CT values for technical replicates 
were averaged and mRNA levels relative to Hprt were calculated by subtracting the CT 
value for Hprt: ΔCT = CT(target) – CT(Hprt). The relative abundance of target mRNA 
levels compared to Hprt was calculated by log 2 conversion of the ΔCT value (2-(CT(target) – 
CT(hprt))). All reactions generated melting curve products with a single dissociation peak. 
 
FACS Analysis 
 Fluorescence-activated cell sorting (FACS) is a specialized type of flow 
cytometry where cells from a heterogeneous population are sorted into separate vessels 
one cell at a time based on the way that each cell scatters light from a laser and its 
fluorescent properties. Cells are stained with fluorophore conjugated antibodies that can 
bind to specific proteins or components on the cell membrane. Fluorophores have a 
unique peak excitation and emission wavelength when excited by lasers, and different 
combinations of fluorophore conjugated antibodies can be used to identify specific cell 
populations based on their cell surface composition.  
 Cell-surface protein staining was done on a single-cell suspension of freshly 
isolated mouse bone marrow after hypotonic lysis of red blood cells. Cells were treated 
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with 2.4 G2 antibody to block non-specific Fc binding, followed by an incubation with a 
mix of FITC-conjugated antibodies against CD3, B220, and Ter119 (all BioLegend), 
CD11b-APC (BioLegend) and Ly6C-PE-Cy7 (BioLegend). After exclusion of 
CD3/B220/Ter119+ cells to exclude T cells, B cells, and erythroid cells, respectively, 
cells were gated and sorted based on the intensity of CD11b and Ly6C staining. 
 FACS-sorted populations were then plated in triplicate at concentrations of 2.5 x 
103/well and 5 x 103/well on 96-well plates, and were cultured directly in OC media 
containing 10 ng/ml MCSF and either 5 ng/ml RANKL or 50 ng/ml TNFα plus 50 ng/ml 
IL-6. After 5-6 days of culture, cells were fixed and stained for TRAP. 
 
Micro-computed tomography (μCT) analysis 
μCT uses x-rays to create cross-sectional images of physical objects that can then 
be used to reconstruct a 3-dimensional model, and uses the term micro because the pixel 
sizes of reconstructed images are in the micrometer range. In addition to imaging, use of 
the μCT is ideal for bone structural analysis because it allows users to make calibrated 
measurements of things like cortical thickness, bone density and trabecular number. Fore 
paws from arthritic mice were scanned on a Scanco μCT 35 at 7 micron resolution. A 
Gaussian filter optimized for use on murine cortical bone was used to reduce background 
noise in the 2-dimensional images. 3-dimensional images were reconstructed from 
filtered 2D images using built-in Scanco software. 
Severity of periarticular erosions was determined by qualitatively scoring 
periarticular erosions of the reconstructed 3D images of the wrist joints on a scale of 0 to 
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3. Four sites in the wrist joint were scored: the ulnar epiphysis where it meets the carpals, 
and third, fourth, and fifth metacarpal epiphyses where they meet the carpals, with a 
maximal score of 12 per paw. A score of 0 indicated normal cortical bone. A 1 indicated 
cortical deformities, while a 2 indicated small perforations in the cortex, and a 3 indicated 
many small perforations, or a large perforation. The scores from the left and right paw of 
each mouse were then averaged so that each mouse has one erosion score. Scores were 
assigned in a blinded fashion, without knowledge of the genotype or antibody treatment. 
 
Statistical Analysis 
 Graphpad Prism software was used for all statistical analysis. Unpaired, 2-tailed 
Student’s t tests were used for all statistical comparisons. P values of less than 0.05 were 
considered statistically significant. 
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RESULTS 
TNFα and IL-6 drive osteoclastogenesis in a RANK/RANKL-independent manner 
 Before exploring the specific requirements of TNFα/IL-6 induced osteoclasts, we 
wanted to verify that we could replicate the RANKL-independent formation of 
osteoclasts from wild-type BMMs cultured with TNFα/IL-6 as described by Yokota, et 
al.37 For these studies, BMMs were expanded from BMCs, and then stimulated with 
TNFα + IL-6 + MCSF (Fig. 6A). Six additional combinations of cytokines were included 
as controls: (1) TNFα + IL-6 + OPG + MCSF, (2) RANKL + MCSF, (3) RANKL + OPG 
+ MCSF, (4) TNFα + MCSF, (5) IL-6 MCSF, and (6) MCSF alone (Fig. 6B-C). Cell 
cultures were fixed and stained for TRAP, a protein that is highly expressed in osteoclasts 
and activated macrophages, and the formation of multinucleated osteoclasts was 
determined by counting the number of TRAP-positive multinucleated cells (cells with 3 
or more nuclei; Fig. 6D). The combination of TNFα and IL-6 successfully drives 
differentiation of large multinucleated TRAP-positive cells, while TNFα or IL-6 alone 
was not able to do so (Fig. 6A, C). TNFα is known to induce expression of RANKL in 
some cell populations, so cultures were also performed with the combinations of TNFα 
and IL-6 in the presence of OPG, a decoy receptor for RANKL. OPG did not 
significantly inhibit TNFα/IL-6-driven osteoclastogenesis (Fig 6A), suggesting that 
TNFα and IL-6 are acting directly on the cells to induce osteoclast differentiation and not 
simply causing osteoclastogenesis through induction of RANKL. As expected, RANKL 
induced efficient osteoclastogenesis, which was more robust than TNFα/IL-6 
osteoclastogenesis at the chosen cytokine doses, and was completely blocked by OPG   
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(Fig. 6B) Interestingly, MSCF plus TNFα induced TRAP expression, but not 
multinucleation, and neither MCSF alone nor MCSF in combination with IL-6 were 
sufficient to induce osteoclast differentiation or TRAP expression (Fig. 6C).   
The results in Figure 6 strongly suggest that TNFα/IL-6 driven osteoclastogenesis 
is RANKL-independent. However, RANK activation and the signaling pathways 
downstream of RANK are widely believed to be essential for osteoclast differentiation.48 
The results in figure 6 and the work of others37 suggest that TNFα directly stimulates 
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osteoclast differentiation independent of RANKL. It is possible, however, that TNFα/IL-
6 could either induce the expression of alternative RANK ligands or somehow directly 
activate RANK.  Thus, we set out to formally exclude the possibility that TNFα/IL-6 
driven osteoclast differentiation is dependent on RANK. Osteoclast precursors 
genetically deficient for RANK were generated by treating Rankfl/fl;Mx1-Cre+ mice with 
poly I:C to induce deletion of RANK in hematopoietic cells (hereafter, RankΔ/Δ). 
Similarly treated age- and sex-matched Rankfl/fl;Mx1-Cre- littermates were used as 
controls (hereafter, RankWT). BMMs were isolated from the femurs of these mice for 
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osteoclast differentiation. Upon stimulation with RANKL, RankΔ/Δ BMMs were unable to 
form osteoclasts and did not exhibit any TRAP expression (Fig. 7B). In contrast, 
quantitation of TRAP+ multinucleated cells (MNCs) revealed that the induction of 
osteoclasts from RankΔ/Δ BMMs stimulated with TNFα and IL-6 was not impaired 
compared to RankWT BMMs (Fig. 7A, B, C). Stimulation of RankΔ/Δ BMMs with TNFα 
also produced a similar phenotype of TRAP+ mononuclear cells as seen when RankWT 
BMMs are treated with TNFα.  
 
RANKL and TNFα/IL-6 induced osteoclasts are derived from the same osteoclast 
precursor population  
 Next we wanted to investigate whether TNFα/IL-6 osteoclasts are derived from 
the same myeloid progenitor cell population as RANKL-induced osteoclasts. The 
predominant osteoclast precursor in murine bone marrow can be identified by flow 
cytometry.   On their surface, these cells express high levels of Ly6C and low levels of 
CD11b (CD11b-/loLy6Chi).  In addition, osteoclast precursors lack staining for the T, B, 
and erythroid cell surface markers, CD3, B220, and Ter119, respectively.41 These CD3-
B220-Ter119-CD11b-/loLy6Chi cells will now be referred to as osteoclast precursors 
(OCPs). FACS sorting was used to isolate four populations of myeloid progenitor cells 
from CD3/B220/Ter119-depleted bone marrow: CD11b-/loLy6Chi (OCPs), 
CD11bhi/Ly6Chi, CD11bhi/Ly6Cint, and CD11b-Ly6C-. The gating strategy used is 
outlined by the dot plots in Figure 8A.  
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Osteoclast precursors comprise 1-2% of the total bone marrow population cell 
population, so when plating 3 x 104 cells/well we expect to get only 300-600 osteoclast 
precursors, which is the rationale for the initial 2 day expansion of total bone marrow 
cells in MCSF. If any of the sort-purified populations are enriched for osteoclast 
precursors, then we would expect them to easily differentiate into osteoclasts when 
compared to total bone marrow (the unsorted population). All four cell populations and 
unsorted bone marrow were cultured directly in the cytokines RANKL plus MCSF or 
TNFα/IL-6 plus MCSF at a density of 5 x 103 cells/well, without prior expansion of 
myeloid precursors in MCSF. 
 TRAP assays of the osteoclast cultures show that both the combination of TNFα 
and IL-6 and RANKL are capable of driving robust osteoclast differentiation in the 
CD11b-/loLy6Chi OCP population (Fig. 8B, C). Little to no osteoclast formation is seen 
under either condition in the unsorted cells, showing that the CD11b-/loLy6Chi population 
is enriched for osteoclast precursors. TRAP positive cells were also seen in the 
CD11bhiLy6Chi cell population was cultured with RANKL, which was not unexpected 
since this population harbors macrophage precursors, and macrophages also express 
TRAP. However, stimulation of the CD11bhiLy6Chi population with TNFα/IL-6 failed to 
produce any multinucleated osteoclasts. Cells in the CD11bhiLy6Cint population were 
unable form osteoclasts under either condition. As expected, some osteoclast formation 
was observed in the CD11b-Ly6C- cell population treated with RANKL, since that 
population includes MDPs (myeloid dendritic cell precursors), which have been 
previously shown to have osteoclast differentiation potential.41 The ability of TNFα/IL-6 
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to stimulate osteoclastogenesis in this population was more diminished than expected, 
compared to the RANKL-stimulated cells. Thus, TNFα/IL-6 osteoclasts appear to be 
derived from the same precursor population as RANKL osteoclasts. However, our 
observation that TNFα/IL-6 fails to induce osteoclast differentiation from the population 
containing MDPs may suggest that the ability of TNFα/IL-6 to induce osteoclast 
differentiation is restricted to fewer subsets of myeloid precursors than RANKL. 
 
TNFα/IL-6 and RANKL osteoclasts express similar markers of osteoclast 
differentiation and function  
RANKL-driven osteoclastogenesis is characterized by the induction of 
transcription factors required for differentiation, and cell surface receptors, anion 
exchangers, and proteases important for their resorptive function.44,60 We examined 
whether TNFα/IL-6 induced osteoclasts express similar key transcription factors and 
genes coding for important functional pathways as in RANKL induced osteoclasts. RNA 
was isolated from TNFα/IL-6 and RANKL-induced osteoclasts, as well as from BMMs 
stimulated with MCSF alone, MCSF plus TNFα, and MCSF plus IL-6 as controls. 
Expression of genes of the OC differentiation program such as Nfatc1, Calcr (calcitonin 
receptor), Itgb3 (integrin β3), and DC-stamp were measured relative to levels of Hprt 
using quantitative real-time PCR. We also examined the expression of genes important 
for resorptive function including Ctsk (cathepsin K), Atp6v0d2 (H+ pump), Acp5 (TRAP), 
and Slc4a2 (anion exchanger 2). Primer sequences for each target gene are listed in Table 
1. 
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Since there is limited multinucleation seen in BMMs cultured with TNFα 
compared to TNFα/IL-6 cultured BMMs, we expected the expression of osteoclast genes 
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to be higher in the cells cultured with both cytokines in combination. While this was the 
case for the expression of Ctsk, for most of the genes examined (Nfatc1, Itgb3, Dcstamp, 
Acp5, Atp6v0d2, and Slc4a2), there was no statistically significant distinction between 
expressions of the genes in TNFα versus TNFα plus IL-6 treated BMMs (Fig. 9). In fact, 
the expression of CalcR expression was significantly lower in the TNFα/IL-6 treated cells 
than the cells treated with only TNFα without IL-6 (Fig. 8). TNFα alone was sufficient to 
induce expression of each of the osteoclast program genes examined (Fig. 8).  This 
suggested to us that TNFα rather than IL-6 drives the expression of genes responsible for 
osteoclast differentiation and function. None of the genes were induced by culture of 
BMMs with MCSF alone (Fig. 9) or IL-6 plus MCSF (data not shown). 
 Comparison of BMMs treated with RANKL to BMMs treated with TNFα or 
TNFα/IL-6 demonstrated more potent induction of the osteoclast transcription program 
across the board. The expression level of the osteoclast marker genes detected was 3-4 
fold higher in the BMMs treated with RANKL than in those treated with TNFα or 
TNFα/IL-6.  
 
TNFα/IL-6 induces osteoclasts with bone-resorbing activity in vitro 
 Bone resorption is the hallmark of functional osteoclasts. While TNFα plus IL-6 
induced osteoclasts express many of the genes representative of the normal osteoclast 
transcriptional program, including genes whose products contribute to resorptive 
function, we wanted to determine whether TNFα/IL-6 osteoclasts are capable of 
resorbing bone.    
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Several different approaches were used to test the resorptive function of TNFα/IL-
6 induced osteoclasts.  Pit formation assays were performed on dentin chips that had been 
cultured with BMMs for two weeks in the presence of TNFα alone, TNFα/IL-6 or 
RANKL. Dentin chips were stained with WGA-lectin and resorption pits were visualized 
by confocal microscopy. TNFα/IL-6 induced osteoclasts capable of resorption as 
demonstrated by the formation of pits and resorption trails (Fig. 10A). No resorption pits 
were observed in the MCSF or TNFα-treated cultures. Pit formation is more dramatic in 
RANKL-driven osteoclast cultures at the concentration of cytokine used, but this likely 
reflects the larger number of osteoclasts formed in these cultures, as discussed in the 
section above. 
Our second assay measured the resorptive function of TNFα/IL-6 osteoclasts by 
growing them on human bone chips. After two weeks, ELISA was used to measure 
carboxy-terminal collagen crosslinks (CTX) in the culture supernatants. CTX is a 
telopeptide that is formed by cleavage of type I collagen by osteoclast proteases during 
bone resorption.  It is a commonly used clinical serum biomarker to measure the rate of 
bone turnover.61 CTX levels in TNFα/IL-6 cultures were significantly higher than 
baseline CTX levels (Fig. 10C). The CTX levels in RANKL cultures trended higher than 
from TNFα/IL-6 cultures, but this difference was not statistically significant (Fig. 10C). 
CTX levels from cultures treated with MCSF alone and TNFα alone contained basal CTX 
levels equivalent those measured in media from no cell control wells.  
The final assay to test bone resorption functionality was designed to look at the 
ability of TNFα/IL-6 osteoclasts to dissolve calcium phosphate in the form of 
 43 
hydroxyapatite, a common reaction which occurs along with matrix degradation and is 
necessary for efficient bone resorption. RANKL- and TNFα/IL-6 induced osteoclasts 
were cultured on a calcium-phosphate matrix for 14 days.  Calcium phosphate was 
visualized using a Von Kossa stain and areas of reduced staining represent resorption of 
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the mineralized matrix. Again, TNFα/IL-6 osteoclasts demonstrate that they have the 
capacity to resorb bone (Fig. 10D). Similar to pit formation on dentin, resorption is less 
intense compared to RANKL cultures, likely reflecting the lower number of osteoclasts 
in cultures (Fig. 10D). As was observed in the other resorption assays, no resorption was 
observed in control wells where BMMs were cultures with MCSF or TNFα. 
Thus, TNFα in combination with IL-6 is capable of inducing formation of 
osteoclast-like cells that are capable of actively resorbing bone in vitro, although they are 
not as potent as RANKL. However, this may be due to the fact that fewer osteoclasts are 
seen in TNFα/IL-6 cultures, rather than TNFα/IL-6 osteoclasts being less efficient at 
resorption on a per cell basis. In contrast, although TNFα alone induces a similar 
transcriptional profile to TNFα/IL-6 osteoclasts, it is not sufficient to induce 
multinucleation or resorptive function.  
Since signaling provided by RANK is thought to be necessary for osteoclast 
resorption, these resorption assays were carried out using RankΔ/Δ BMMs to determine if 
RANK is necessary for resorption in TNFα/IL-6 induced osteoclasts. In contrast to 
RANKL driven osteoclastogenesis, TNFα/IL-6 induced osteoclasts are capable of 
resorptive function in the absence of RANK. TNFα/IL-6 induced osteoclasts from 
RankΔ/Δ BMMs form resorption pits on dentin chips as demonstrated by WGA-lectin 
staining (Fig. 10B) and release similar levels of CTX as measured by ELISA on 
supernatants from human bone chip cultures those generated by TNFα/IL-6 RankWT 
osteoclasts (Fig. 10C). Similarly, Von Kossa staining of hydroxyapatite matrix that had 
been cultured with TNFα/IL-6–induced RankΔ/Δ osteoclasts revealed areas of resorption 
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(Fig. 10E). In each of the assays, the degree of resorption was similar to that seen in 
TNFα/IL-6–induced RankWT osteoclasts. These data and the data from Figure 6 show that 
TNFα/IL-6-mediated osteoclast formation and resorption remains intact in the absence of 
RANK, indicating that these cytokines activate the osteoclast program through other 
receptors. 
 
NFATc1 and innate immune receptor co-stimulation is required for TNFα/IL-6 
induced osteoclastogenesis  
NFATc1 is the primary transcription factor responsible for driving osteoclast 
differentiation and bone resorption, and its expression is induced downstream of RANK 
signaling. In NFATc1-deficient osteoclast progenitors, stimulation with RANKL fails to 
promote osteoclastogenesis in vitro.47,62 Since TNFα/IL-6–induced RankΔ/Δ osteoclasts 
appear to be activated through a RANK-independent pathway, we next asked whether the 
activity of NFATc1 was still required for multinucleation and expression of the osteoclast 
transcriptional program. 
To answer this question we performed osteoclast differentiation assays using 
BMMs that were deficient for NFATc1. Nfatc1fl/fl;Mx1-Cre+ mice were treated with poly 
I:C to generate Nfatc1Δ/Δ BMMs, with sex-matched littermates lacking Mx1-Cre treated 
similarly serving as wild-type controls. We found that the combination of TNFα and IL-6 
failed to induce both TRAP positivity and multinucleation of Nfatc1Δ/Δ BMMs, which 
looked morphologically similar to BMMs treated with only MCSF (Fig 11).  Thus, while 
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TNFα/IL-6 does not require RANK to initiate the intracellular molecular signaling 
leading to osteoclastogenesis, the pathway they activate also requires the activity of 
NFATc1.  
We next wanted to investigate other signaling requirements of TNFα/IL-6-
induced osteoclasts. Similar to T-cell activation, RANKL-driven osteoclastogenesis 
requires a co-stimulatory signal. For osteoclasts, this signal is provided by ligation of 
innate immune receptors, such as TREM2 and OSCAR, resulting in phosphorylation of 
their associated signaling partners, DAP12 and FcRγ, respectively (Fig 2). Mice lacking 
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DAP12 exhibit osteopetrosis that is severely exacerbated by compound deletion of FcRγ. 
In the absence of DAP12 and FcRγ, mononuclear non-functional osteoclasts are 
generated upon stimulation of BMMs with RANKL.63 However, in some contexts, such 
as ovariectomy stimulated bone loss, mice lacking DAP12 are able to form 
multinucleated, functional osteoclasts.45 If TNFα/IL-6 driven osteoclastogenesis does not 
require co-stimulation through DAP12, it would providing a possible explanation for this 
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previously unexplained phenomenon in Dap12-/- mice. Therefore we set out to examine 
whether TNFα/IL-6 driven osteoclastogenesis requires ITAM-mediated DAP12 
signaling. We tested this hypothesis by culturing BMMs from WT, Dap12-/- and Dap12-/-
;Fcrγ-/- mice with TNFα/IL-6., Similar to RANKL-stimulation, TNFα/IL-6 required 
ITAM-mediated innate immune receptor co-stimulation (Fig. 12).  
 
Blockade of IL-6 receptor inhibits TNFα/IL-6-mediated osteoclastogenesis in vitro 
 We ultimately want to show that TNFα/IL-6 generated osteoclasts are relevant in 
vivo, contributing to pathological periarticular bone erosions in inflamed joints. The 
clinical implication of finding this would be to suggest that for highly erosive RA, 
targeted inhibition of TNFα or IL-6 might be most effective at preventing new erosions. 
First we wanted to determine if TNFα/IL-6 osteoclast formation would be inhibited by 
blocking IL-6 signaling. In IL-6 signaling, IL-6 forms a complex with its receptor IL-6 
receptor (IL-6R), which then associates with the transmembrane protein gp130 to initiate 
internal signaling cascades leading to the expression of proliferative genes and 
antiapoptotic genes, among others.64 IL-6R exists in two forms, a membrane-bound form 
and a soluble form. Most cells in the body do not express IL-6R, however many cells 
express gp130, and cells that do not express membrane-bound IL-6R can be stimulated 
by the binding of IL-6-soluble IL-6R complex to gp130, in a mechanism called IL-6 
trans-signaling.64 IL-6 trans-signaling promotes the pro-inflammatory effects of IL-6 and 
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thus 
is an actively studied pathway with proven murine IL-6R antibodies readily available, 
thus this presented a logical mechanism for inhibiting TNFα/IL-6 osteoclast formation in 
vitro and in vivo. 
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 The anti-mouse IL-6R antibody (MR16-1) has been used successfully in previous 
in vivo models and was generously provided by Genentech. MR16-1 targets both the 
membrane-bound and soluble forms of IL-6R. We hypothesized that if the antibody is 
functional, it should prevent IL-6 signaling in TNFα/IL-6 cultures, and thus BMMs in 
cultures containing MR16-1 should form TRAP-positive mononuclear cells, as though 
they were cultured with TNFα alone. We tested this hypothesis by pre-incubating BMMs 
with the IL6R blocking antibody or an Fc control antibody for 30 minutes prior to 
addition of TNFα/IL-6, in order to give the antibody time to bind its target. Optimal 
concentration of the antibody in vitro was determined by conducting a dose-response 
curve, treating cells with 0.02, 0.2, 2 and 20 μg/mL of antibody (Fig 13). We found that 
the antibody resulted in a dose-dependent inhibition of TNFα/IL-6 osteoclast formation 
with a partial reduction in osteoclast formation at 2 μg/mL and complete inhibition at 20 
μg/mL (Fig. 13A, C).  In contrast, the IgG2a isotype control at the same concentrations as 
the IL-6R antibody had no effect on the formation of osteoclasts after TNFα/IL-6 
stimulation (Fig 13B, C).  
 BMM cultures treated with RANKL were also treated with 20 μg/mL of anti-
mouse IL-6R antibody and IgG2a isotype control antibody, to determine whether the 
antibody blocked osteoclast formation non-specifically. RANKL-induced osteoclast 
formation was unperturbed by IL-6R blockade and thus is independent of IL-6 signaling 
(Fig 12 B). 
 Our observations suggested to us that the IL-6R antibody successfully inhibits IL-
6 signaling in osteoclast precursors preventing TNFα/IL-6 driven osteoclast formation in 
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vitro. Moreover, it appeared to be effective at relatively low concentrations, and thus 
could viably be used to block TNFα/IL-6 induced osteoclastogenesis, and the resultant 
bone erosions, in an in vivo mouse model of arthritis. 
  
IL-6R blockade does not significantly protect against periarticular bone erosion in 
RankΔ/Δ arthritic mice 
 Having shown that TNFα/IL-6 induced osteoclasts develop independently of 
RANK-RANKL signaling, and that they require IL-6R signaling, we set out to determine 
the in vivo relevance of these cells in arthritic mice. Using the K/BxN serum transfer 
arthritis model, we induced arthritis in RankWT and RankΔ/Δ mice. Arthritis is induced in 
this model by injecting serum from K/BxN transgenic mice that spontaneously develop 
transient arthritis.  Auto-antibodies in this arthritogenic serum attack joint tissues in the 
recipient mice, promoting inflammation and joint destruction. We felt this was an ideal 
model for our experiment because it robustly induces both TNFα and IL-6 with 3 to 6 
days of serum transfer.53 Importantly, IL-6 is not required for the development of 
inflammatory arthritis as Il-6-/- mice develop arthritis with similar severity to wild-type 
mice.65 RankWT and RankΔ/Δ mice were treated simultaneously with either anti-mouse IL-6 
receptor antibody (MR16-1) or IgG2a isotype control antibody at the time of serum 
transfer. Additional antibody was administered every three days for two weeks, in an 
attempt to achieve maximal inhibition of IL-6R signaling. We hypothesized that if 
TNFα/IL-6 induced osteoclasts contribute to the pathological bone erosion seen in 
RankΔ/Δ mice, then the IL-6R antibody should reduce both periarticular bone erosions and  
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osteoclast formation on histology, when compared to RankΔ/Δ mice treated with the 
isotype control antibody.  
 Clinical severity of the arthritis was tracked every 2 days throughout the course of 
the experiment using qualitative scores of 0-3 per paw, with a maximal score of 12 per 
mouse. Scoring was based on the severity of dactylitis (swelling of the carpals and 
phalanges), and swelling of the paw and ankle. All of the mice had baseline clinical 
scores of 0 and achieved maximal scores within a few days of the induction of arthritis 
regardless of genotype or antibody treatment. (Fig. 14A) The lack of an effect on 
inflammation by IL-6R antibody was expected, since inflammation in this mouse model 
is independent of IL-6. Changes in paw thickness, which were measured simultaneously 
with clinical scores, followed a similar trajectory as the clinical scores, with no statistical 
differences between the groups based on genotype or antibody. (Fig. 14B) 
 After two weeks of antibody treatment, the mice were sacrificed and forepaws 
were collected for μCT analysis (Fig. 14C). Reconstructed 3D images of the paws were 
scored using a semi-quantitative scale by a blinded observer. The scores of the two paws 
were averaged, with a maximal score of 12 per mouse, with a higher score indicating 
Figure 14. Blockade of IL-6 signaling with a monoclonal IL-6 receptor antibody does 
not protect RANK deficient mice from bone erosions in the serum transfer model of 
arthritis. (A,B) Treatment with either IL-6R antibody or isotype control does not diminish 
(A) clinical scores of inflammatory arthritis or (B) paw swelling in either Rank
WT 
or Rank
Δ/Δ
 
mice given arthritogenic serum. (C) Representative μCT images of forepaws from Rank
WT
 or 
Rank
Δ/Δ
 mice treated with IL-6R antibody or isotype control. (D) Combined erosions scores 
from both paws from mice in each group. Data were obtained from a total of 23 mice, from 
two different experiments, and scores were assigned in a blinded manner. (E) Expression of 
RANK relative to the house keeping gene GAPDH in cells from bone marrow of Rank
WT
  
and Rank
Δ/Δ
 mice as measured by qPCR. 
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more severe erosions. RankΔ/Δ mice are modestly protected from periarticular bone 
erosion formation when compared to RankWT, as was observed in our preliminary data 
(Fig. 3). However erosion scores in the RankΔ/Δ IL-6R antibody treated group were not 
significantly different from those in the RankΔ/Δ isotype antibody treated group, 
suggesting that treatment with IL-6R antibody failed to further protect against bone 
erosions (Fig 14D). There was also no difference observed in the RankWT treated with the 
anti-IL6R antibody versus those treated with the isotype control. This result was expected 
due to fact that these mice have a functional RANKL-RANK axis capable of driving 
maximal osteoclast formation. 
In addition to paws collected for μCT analysis, bone marrow was collected for 
osteoclast differentiation assays and for mRNA, to verify deletion of RANK. qPCR 
analysis of the bone marrow revealed that over 95% deletion of Rank was achieved in the 
bone marrow (Fig. 13E). Furthermore, as expected, RankΔ/Δ BMMs failed to form 
osteoclasts upon RANKL stimulation while RankWT BMMs formed osteoclasts upon 
RANKL stimulation regardless of antibody treatment, and all groups formed osteoclasts 
upon stimulation with TNFα/IL-6 (data not shown). This suggests to us that RANK was 
successfully and efficiently deleted in osteoclast precursors, and precludes inefficient 
RANK deletion as an explanation for the discrepancy between our observations and our 
hypothesis. 
Hind paws were also collected for histological analysis to both visualize 
osteoclast numbers and microscopic bone erosion.  These samples were still being 
processed at the time this thesis was prepared.  
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DISCUSSION 
 Excessive resorption by osteoclasts is critical to the pathological formation of 
periarticular bone erosions, which contribute to joint destruction and increased morbidity 
in patients with rheumatoid arthritis and other inflammatory arthritides.  Although 
RANKL is required for osteoclast differentiation and resorbing activity under most 
circumstances, recent reports suggest that some inflammatory cytokines commonly found 
in inflamed joints may substitute for RANKL, at least in vitro. In particular, the cytokines 
TNFα and IL-6 have been shown to drive osteoclast differentiation from mouse myeloid 
precursors in vitro.37 Differentiation of osteoclasts was not affected by the presence of 
osteoprotegerin, a decoy receptor for RANKL that inhibits RANKL-induced 
osteoclastogenesis. This suggests that TNFα and IL-6 act directly on myeloid precursors 
to activate the osteoclast differentiation program. While it appears that RANKL is not 
required, other components of the signaling pathway involved in TNFα/IL-6-induced 
osteoclastogenesis pathway have not been resolved. To investigate this pathway further, 
we established an in vitro system to differentiate osteoclast-like cells with TNFα and IL-6 
from mouse myeloid precursors. Similar to incubation with RANKL and MCSF, bone 
marrow macrophages cultured in the combination of TNFα and IL-6 form large TRAP-
positive multinucleated cells. At the doses used, RANKL was more effective at inducing 
osteoclast formation than TNFα/IL-6. Moreover, higher doses of TNFα/IL-6 failed to 
further enhance osteoclast differentiation (data not included). Incubation of bone marrow 
macrophages with TNFα led to the formation of TRAP-positive cells with limited 
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multinucleation. In contrast, incubation with MCSF alone or IL-6 with MCSF induced 
neither TRAP-positivity nor multinucleation. 
It is widely held that activation of RANK is required for initiation of the 
downstream signaling pathways that lead to osteoclast differentiation, and that TNFα 
potentiates osteoclast formation indirectly, through induction of RANKL on stromal 
cells. However, the observation that stimulation of BMMs with TNFα/IL-6 results in 
osteoclast formation of independent of RANKL is that this combination of cytokines 
must either 1) induce expression other ligands that act through RANK, 2) somehow 
directly activate RANK or 3) act directly on the osteoclast precursor to promote 
differentiation independent of RANK. In order to further elucidate the molecular 
requirements of TNFα/IL-6 osteoclasts, adult Rankfl/fl;Mx1-Cre+ mice were treated with 
poly I:C to generate RankΔ/Δ mice lacking RANK in myeloid cells. Four weeks later, 
BMMs were isolated from RankΔ/Δ and RankWT mice for osteoclast differentiation assays. 
As expected, RANKL was unable to induce osteoclast differentiation from RankΔ/Δ 
BMMs. In contrast, both RankΔ/Δ and RankWT BMMs formed osteoclasts in response to 
TNFα/IL-6. This suggests that TNFα and IL-6 act directly on osteoclast precursors to 
activate the osteoclast differentiation program, independently of the RANK-RANKL 
axis. 
While precursors of several different cell types within the myeloid lineage possess 
osteoclast differentiation capability in certain circumstances, the majority of osteoclast 
precursor activity from murine bone marrow in in vitro assays resides within a population 
of CD11b-/lowLy6Chi myeloid cells.41 We verified that these precursors formed osteoclasts 
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in response to TNFα/IL-6 as well. Additionally, we observed that TNFα/IL-6 was unable 
to stimulate osteoclastogenesis in other myeloid lineage cells that can form osteoclasts by 
RANKL stimulation. These data indicate that TNFα/IL-6 induces osteoclast formation 
from the identical population of precursors as RANKL, and suggest the possibility that 
TNFα/IL-6-mediated osteoclastogenesis is limited to a more restricted set of myeloid 
lineages than RANKL.   
Similar to RANKL-induced osteoclasts, we also found that TNFα/IL-6 osteoclasts 
expressed a transcriptional program similar to RANKL osteoclasts, including NFATc1, 
Integrin β3, DC-STAMP, Atp6v0d2, TRAP, cathepsin K, calcitonin receptor, and anion 
exchange protein 2. The reduced expression of osteoclast genes induced by TNFα/IL-6 
compared to RANKL likely reflects the differences in the percentage of cells in culture 
that have formed mature osteoclasts. Because less osteoclast formation is seen in the 
TNFα/IL-6 treated BMMs, the differences in expression between RANKL and TNFα/IL-
6 osteoclasts could be explained by the fact that there are fewer osteoclasts in the TNFα 
cultures. Regardless of whether that is the case, it is clear that TNFα is capable of driving 
the expression of many of the genes that define the osteoclast transcription program and 
are necessary for osteoclast function even in the absence of RANKL.  
Resorption assays performed on osteoclasts formed in response to TNFα/IL-6 
showed that they also possess resorptive function. TNFα/IL-6 osteoclasts formed 
resorption pits on dentin, generated CTX peptide in supernatant when cultured with bone 
fragments, and were able to resorb hydroxyapatite matrices as well. Since RANK is 
widely considered to be required for resorbing activity by osteoclasts, resorption assays 
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were also conducted with RankΔ/Δ BMMs stimulated with TNFα/IL-6. We found that 
RankWT and RankΔ/Δ TNFα/IL-6 derived osteoclasts resorbed dentin, bone, and 
hydroxyapatite to a similar extent, indicating that activation of RANK is not required for 
resorption by these cells. Taken together, these data indicate that in vitro, TNFα/IL-6 
directly induces RANK-independent formation of osteoclast-like cells with similar 
transcriptional and functional characteristics as RANK-generated osteoclasts. 
In our efforts to further characterize TNFα/IL-6 osteoclasts, we next investigated 
whether RANKL and TNFα/IL-6 induced osteoclast formation shares the requirement for 
the transcription factor, NFATc1, as well as co-stimulatory pathways initiated by ITAM-
containing adapter molecules DAP12 and FcRγ. Neither RANKL nor TNFα/IL-6 was 
capable of inducing osteoclast formation in NFATc1-deficient BMMs, highlighting the 
importance of NFATc1 for driving the osteoclast transcriptional program. Likewise, 
TNFα/IL-6 mediated osteoclastogenesis required activation of co-stimulatory pathways 
through DAP12.  
An interesting observation from our gene expression and resorption analysis was 
that BMMs incubated with TNFα expressed similar levels of the genes required for 
osteoclast differentiation and function as TNFα/IL-6 osteoclasts, yet rarely formed 
multinucleated cells and were unable to resorb bone in vitro. This raises the question of 
what role IL-6 is playing to drive TNFα/IL-6-mediated osteoclastogenesis?  One 
possibility is that IL6 promotes the expansion of OCP cells and this expansion facilitates 
differentiation. Indeed, the addition of IL-6 to BMMs cultured with MCSF increased cell 
proliferation. Previously published data that IL-6 signaling induces proliferative genes 
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supports this hypothesis. In future experiments we plan to explore this possibility by co-
culturing BMMs with both TNFα/IL-6 and the drug hydroxyurea (HU). HU is an 
inhibitor of ribonucleotide reductase and subsequent deoxyribonucleotide synthesis. HU 
does not kill cells, but stops proliferation.66 We hypothesize that if the required role IL-6 
in TNFα/IL-6-mediated osteoclastogenesis is a proliferative one, then BMMs cultured 
with TNFα/IL-6 in combination with HU should look morphologically identical to 
BMMs cultured with TNFα alone. An alternative hypothesis is that IL-6 reduces the 
threshold required to effectively activate NFATc1. This is based on a recent model that 
proposes that basal levels of phospholipase-Cγ2 (PLCγ2)/calcium signaling, which are 
mediated by DAP12/FcRγ ITAM-mediated induction, need to be activated to higher 
levels to effectively activate NFATc1 and osteoclastogenesis.46 RANKL signaling 
induces strong calcium signaling, whereas TNFα induces much weaker calcium signaling 
and requires higher basal of PLCγ2/calcium signaling to induce osteoclastogenesis.46 
Although no link between IL-6 and PLCγ2 has been established, this publication suggests 
the possibility that IL-6 may increase the basal level of PLCγ2/calcium signaling, 
allowing co-stimulation with TNFα/IL-6 to achieve the level of calcium signaling 
necessary to effectively activate NFATc1. This can easily be examined by comparing 
calcium flux and gene expression or phosphorylation of PLCγ2 in BMMs cultured with 
TNFα/IL6 versus TNFα alone. Admittedly, the lack of increase in expression of 
NFATc1-target genes seen in BMMs cultured in TNFα versus TNFα/IL-6 diminishes the 
plausibility of this hypothesis. 
 Although RANK is dispensable for TNFα/IL-6 induced osteoclastogenesis, this 
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pathway does require the IL-6 receptor (IL-6R). The IL-6R blocking antibody MR16-1, 
but not isotype control antibody, completely abrogated TNFα/IL-6 induced 
osteoclastogenesis in vitro. As expected, the IL-6R antibody had no effect on the ability 
of RANKL to promote osteoclast differentiation.  
The ability of TNFα/IL-6 to support osteoclastogenesis suggests that RANK-
independent osteoclast formation and bone erosion may occur in a sufficiently inflamed 
environment.  In a previously conducted experiment in the Aliprantis laboratory, arthritis 
was induced in RankWT and RankΔ/Δ mice by transfer of serum from K/BxN mice. As 
expected no differences in maximal inflammation as measured by clinical score, paw 
thickness measurements, and histopathology were seen in RankΔ/Δ mice. Surprisingly, 
given the pivotal role RANK plays in osteoclast formation under most circumstances, we 
observed only modestly reduced bone erosion in RankΔ/Δ mice. This result is in contrast to 
previous literature in which rank was found to be essential for erosion formation. One 
difference may be that in our experiments, the Rank gene was not deleted until mice were 
at least 8 weeks of age, ensuring they were skeletally mature at the time of arthritis 
induction. These results suggested to us that inflammatory bone erosion is only partially 
dependent on RANK mediated osteoclastogenesis, and that TNFα/IL-6 induced 
osteoclasts may contribute to inflammatory bone erosions in this setting. If this is the 
case, then inhibition of IL-6R should further protect against pathological bone erosion. 
To test this hypothesis, we induced arthritis in RankWT and RankΔ/Δ mice with K/BxN 
serum transfer, and simultaneously treated them with either an IL-6R blocking antibody 
or an isotype control antibody. Clinical scores and measures of paw inflammation 
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indicated that all mice achieved maximal inflammation regardless of genotype or 
treatment with IL-6R antibody. This was expected, as neither RANK nor IL-6 is required 
for inflammation in the K/BxN serum transfer model.65 The carpal bones were analyzed 
by μCT and no differences in erosion scores were identified with IL6R blockade, 
contrary to what we expected.  One possible explanation for this result was that our 
methodology only yielded partial Rank gene deletion, which could result in a population 
of RANK-positive osteoclast precursors within the inflamed synovium. However, Rank 
mRNA analysis of bone marrow from arthritic RankΔ/Δ mice revealed a greater than 95% 
deletion of RANK compared to RankWT mice, suggesting that this was not the reason for 
our results. Another possible explanation is that inflammatory cytokines are inducing 
expression of RANK in synovial macrophages in the inflamed joint, and then RANKL 
induces them to differentiate into osteoclasts. The cellular origins of synovial 
macrophages are unclear, and it is possible that the Mx1-Cre system may not efficiently 
induce Rank deletion in these cells. It is possible that synovial macrophages, which play 
an important role in driving pathogenesis by production of inflammatory cytokines, may 
also be differentiating into osteoclasts via intact RANKL/RANK signaling.67 To exclude 
this explanation for our results, we will induce arthritis in RankWT and RankΔ/Δ mice with 
K/BxN serum transfer. During peak inflammation synovial cells from inflamed joints will 
be isolated and incubated with either RANKL or TNFα/IL-6.    We will also look to see 
whether TNFα/IL-6 induces osteoclastogenesis in these cells and whether it is susceptible 
to inhibition by IL-6R antibody. Other explanations for our observations could include 
that the dose of the antibody used in vivo was too low to saturate the available IL-6Rs or 
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that the antibody was unable to penetrate the joint tissue where it would be needed to be 
effective. Finally, there could also be other combinations of inflammatory cytokines that 
are capable of inducing osteoclast differentiation that have not yet been identified. 
The influence of inflammatory cytokines in pathological bone resorption in RA is 
well established, particularly their ability to drive osteoclastogenesis through induction of 
RANKL on synovial fibroblasts and osteoblasts.43,68 Much work remains to be done to 
elucidate the mechanisms by which inflammatory cytokines drive osteoclast 
differentiation. Our work builds upon the finding by Yokota at al.37 showing that TNFα 
and IL-6 are capable of driving osteoclasatogenesis independent of RANKL. We have 
shown that TNFα and IL-6 operate independently of RANK, but still require the same 
transcriptional and co-stimulatory pathways as RANKL driven osteoclasts. Although in 
one series of experiments, we were unsuccessful at abrogating bone erosions in vivo by 
treating mice with IL-6R antibody, we believe it is important to continue to determine the 
relative contribution of TNFα/IL-6 driven osteoclasts to periarticular bone erosions in 
RA. It is hoped that additional efforts to reveal the mechanisms behind the function of 
inflammatory-driven osteoclastogenesis will result in more efficient treatment of patients 
with RA and increase our ability to prevent further bone damage.  
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